Anders Fink-Jensen

Nov 14, 2024 | onlinelibrary.wiley.com | Anders Fink-Jensen |Christoph U. Correll

LETTER TO THE EDITOR Letter to the Editor Concerning “Glucagon-Like Peptide Agonists for Weight Management in Antipsychotic-Induced Weight Gain: A Systematic Review and Meta-Analysis” Anders Fink-Jensen,  Anders Fink-Jensen Mental Health Centre Copenhagen, Mental Health Services—Capital Region of Denmark, Copenhagen, Denmark Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, DenmarkSearch for more papers by this authorChristoph U.

Nov 8, 2024 | onlinelibrary.wiley.com | Anders Fink-Jensen |Christoph U. Correll

Patients with mental disorders have a significantly reduced lifespan,1 with overweight/obesity and cardiometabolic-related death being the biggest contributors. Both the underlying mental illness and treatments, especially antipsychotics, contribute to this increased cardiometabolic risk, creating a dilemma between efficacy and desired safety.

May 10, 2024 | onlinelibrary.wiley.com | Henrik Kehlet |Anders Fink-Jensen |Simon Kornvig |Christoffer Calov Jørgensen

1 INTRODUCTION AND BACKGROUND Psychiatric disorders and psychopharmacological treatment have been identified as important risk factors for increased length of stay (LOS) and readmission after hip and knee replacement, regardless of important preoperative comorbidities.1, 2 However, it is less clear whether this effect is due to the psychiatric disorder, pharmacological side effects or a combination.

Nov 24, 2023 | nature.com | Lorenzo Leggio |Christian S Hendershot |Mehdi Farokhnia |Anders Fink-Jensen |Mette Kruse Klausen

Preclinical and initial human studies suggest that glucagon-like peptide-1 receptor agonists may be promising treatments for alcohol use disorder, but existing approved treatments should be used until safety and efficacy is demonstrated in clinical trials.

Nov 21, 2023 | onlinelibrary.wiley.com | Robert F. Kushner |Anders Fink-Jensen |Ofir Frenkel

What is already known? There is a strong bidirectional link between obesity and depression. Several antidepressants have been shown to induce weight gain, thus increasing the risk of obesity. People with depressive episodes are often excluded from weight loss trials. Participants with major depressive disorder or other severe psychiatric disorders, such as schizophrenia or bipolar disorder, were excluded from the STEP program.